{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:15:33Z","timestamp":1792088133304,"version":"4.4.0"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41571-025-01100-3","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T11:39:32Z","timestamp":1764243572000},"page":"121-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Personalized intensification of treatment for hormone-sensitive prostate cancer"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2216-5650","authenticated-orcid":false,"given":"Michael A.","family":"Cilento","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2698-3220","authenticated-orcid":false,"given":"Lisa M.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0398-6018","authenticated-orcid":false,"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"1100_CR1","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/ijc.35278","volume":"156","author":"AM Filho","year":"2024","unstructured":"Filho, A. M. et al. The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide. Int. J. Cancer 156, 1336\u20131346 (2024).","journal-title":"Int. J. Cancer"},{"key":"1100_CR2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James, N. D. et al. The lancet commission on prostate cancer: planning for the surge in cases. Lancet 403, 1683\u20131722 (2024).","journal-title":"Lancet"},{"key":"1100_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/jnci\/djaa068","volume":"113","author":"A Jemal","year":"2021","unstructured":"Jemal, A., Culp, M. B., Ma, J., Islami, F. & Fedewa, S. A. Prostate cancer incidence 5 years after US preventive services task force recommendations against screening. J. Natl Cancer Inst. 113, 64\u201371 (2021).","journal-title":"J. Natl Cancer Inst."},{"key":"1100_CR4","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy, F. C. et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N. Engl. J. Med. 388, 1547\u20131558\u00a0(2023).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard, G. et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 399, 447\u2013460 (2022).","journal-title":"Lancet"},{"key":"1100_CR6","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1002\/cncr.31384","volume":"124","author":"JT Helgstrand","year":"2018","unstructured":"Helgstrand, J. T. et al. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-a population-based analysis of 2 national cohorts. Cancer 124, 2931\u20132938 (2018).","journal-title":"Cancer"},{"key":"1100_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford, P. et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 86, 148\u2013163 (2024).","journal-title":"Eur. Urol."},{"key":"1100_CR8","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer V.1.2025. National Comprehensive Cancer Network https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf (accessed 31 January 2025)."},{"key":"1100_CR9","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.urology.2007.08.055","volume":"70","author":"DJ Hernandez","year":"2007","unstructured":"Hernandez, D. J., Nielsen, M. E., Han, M. & Partin, A. W. Contemporary evaluation of the D\u2019amico risk classification of prostate cancer. Urology 70, 931\u2013935 (2007).","journal-title":"Urology"},{"key":"1100_CR10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ijrobp.2022.12.035","volume":"116","author":"PL Nguyen","year":"2023","unstructured":"Nguyen, P. L. et al. Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: meta-analysis of the nrg oncology\/radiation therapy oncology group 9202, 9413, and 9902 phase 3 randomized trials. Int. J. Radiat. Oncol. Biol. Phys. 116, 521\u2013529 (2023).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1100_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.eururo.2017.09.013","volume":"73","author":"SK Van Den Eeden","year":"2018","unstructured":"Van Den Eeden, S. K. et al. A Biopsy-based 17-gene Genomic prostate score as a predictor of metastases and prostate cancer death in surgically treated men with clinically localized disease. Eur. Urol. 73, 129\u2013138 (2018).","journal-title":"Eur. Urol."},{"key":"1100_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1470-2045(10)70295-3","volume":"12","author":"J Cuzick","year":"2011","unstructured":"Cuzick, J. et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 12, 245\u2013255 (2011).","journal-title":"Lancet Oncol."},{"key":"1100_CR13","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.euo.2024.01.004","volume":"7","author":"AE Ross","year":"2024","unstructured":"Ross, A. E. et al. External validation of a digital pathology-based multimodal artificial intelligence architecture in the NRG\/RTOG 9902 phase 3 trial. Eur. Urol. Oncol. 7, 1024\u20131033 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1100_CR14","first-page":"293","volume":"1","author":"C Huggins","year":"1941","unstructured":"Huggins, C. & Hodges, C. V. Studies on prostatic cancer. I. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1, 293\u2013297 (1941).","journal-title":"Cancer Res."},{"key":"1100_CR15","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland, S. J. et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N. Engl. J. Med. 389, 1453\u20131465 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR16","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1002\/cncr.25993","volume":"117","author":"SE Cotter","year":"2011","unstructured":"Cotter, S. E. et al. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer 117, 3925\u20133932 (2011).","journal-title":"Cancer"},{"key":"1100_CR17","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","volume":"396","author":"CC Parker","year":"2020","unstructured":"Parker, C. C. et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet 396, 1413\u20131421 (2020).","journal-title":"Lancet"},{"key":"1100_CR18","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","volume":"21","author":"A Kneebone","year":"2020","unstructured":"Kneebone, A. et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 21, 1331\u20131340 (2020).","journal-title":"Lancet Oncol."},{"key":"1100_CR19","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","volume":"21","author":"P Sargos","year":"2020","unstructured":"Sargos, P. et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 21, 1341\u20131352 (2020).","journal-title":"Lancet Oncol."},{"key":"1100_CR20","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","volume":"20","author":"C Carrie","year":"2019","unstructured":"Carrie, C. et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 20, 1740\u20131749 (2019).","journal-title":"Lancet Oncol."},{"key":"1100_CR21","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","volume":"399","author":"A Pollack","year":"2022","unstructured":"Pollack, A. et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet 399, 1886\u20131901 (2022).","journal-title":"Lancet"},{"key":"1100_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.eururo.2024.07.026","volume":"86","author":"CC Parker","year":"2024","unstructured":"Parker, C. C. et al. Randomised trial of no, short-term, or long-term androgen deprivation therapy with postoperative radiotherapy after radical prostatectomy: results from the three-way comparison of RADICALS-HD (NCT00541047). Eur. Urol. 86, 422\u2013430 (2024).","journal-title":"Eur. Urol."},{"key":"1100_CR23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1607529","volume":"376","author":"WU Shipley","year":"2017","unstructured":"Shipley, W. U. et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N. Engl. J. Med. 376, 417\u2013428 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-025-00937-0","author":"P Ravi","year":"2025","unstructured":"Ravi, P. et al. Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancer. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-025-00937-0 (2025).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1100_CR25","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","volume":"80","author":"LF Valle","year":"2021","unstructured":"Valle, L. F. et al. A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur. Urol. 80, 280\u2013292 (2021).","journal-title":"Eur. Urol."},{"key":"1100_CR26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki, D. et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur. Urol. 86, 164\u2013182 (2024).","journal-title":"Eur. Urol."},{"key":"1100_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/JU.0000000000001375","volume":"205","author":"WT Lowrance","year":"2021","unstructured":"Lowrance, W. T. et al. Advanced prostate cancer: AUA\/ASTRO\/SUO guideline PART I. J. Urol. 205, 14\u201321 (2021).","journal-title":"J. Urol."},{"key":"1100_CR28","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1200\/JCO.20.03256","volume":"39","author":"KS Virgo","year":"2021","unstructured":"Virgo, K. S. et al. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. J. Clin. Oncol. 39, 1274\u20131305 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR29","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein, J. I. et al. The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am. J. Surg. Pathol. 40, 244\u2013252 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"1100_CR30","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.eururo.2019.03.016","volume":"75","author":"D Tilki","year":"2019","unstructured":"Tilki, D., Preisser, F., Graefen, M., Huland, H. & Pompe, R. S. External validation of the european association of urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a european cohort. Eur. Urol. 75, 896\u2013900 (2019).","journal-title":"Eur. Urol."},{"key":"1100_CR31","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","volume":"17","author":"GM Duchesne","year":"2016","unstructured":"Duchesne, G. M. et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 17, 727\u2013737 (2016).","journal-title":"Lancet Oncol."},{"key":"1100_CR32","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(17)30426-6","volume":"18","author":"GM Duchesne","year":"2017","unstructured":"Duchesne, G. M. et al. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 18, 1192\u20131201 (2017).","journal-title":"Lancet Oncol."},{"key":"1100_CR33","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1200\/JCO.23.01157","volume":"42","author":"R Aggarwal","year":"2024","unstructured":"Aggarwal, R. et al. PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19). J. Clin. Oncol. 42, 1114\u20131123 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR34","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1201546","volume":"367","author":"JM Crook","year":"2012","unstructured":"Crook, J. M. et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N. Engl. J. Med. 367, 895\u2013903 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR35","doi-asserted-by":"publisher","first-page":"EVIDoa2300251","DOI":"10.1056\/EVIDoa2300251","volume":"2","author":"SJ Freedland","year":"2023","unstructured":"Freedland, S. J. et al. Enzalutamide and quality of life in biochemically recurrent prostate cancer. NEJM Evid. 2, EVIDoa2300251 (2023).","journal-title":"NEJM Evid."},{"key":"1100_CR36","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","volume":"35","author":"W Xie","year":"2017","unstructured":"Xie, W. et al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J. Clin. Oncol. 35, 3097\u20133104 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2510310","author":"ND Shore","year":"2025","unstructured":"Shore, N. D. et al. Improved survival with enzalutamide in biochemically recurrent prostate cancer. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2510310 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR38","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1470-2045(20)30730-0","volume":"22","author":"LA Gharzai","year":"2021","unstructured":"Gharzai, L. A. et al. Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. Lancet Oncol. 22, 402\u2013410 (2021).","journal-title":"Lancet Oncol."},{"key":"1100_CR39","doi-asserted-by":"publisher","unstructured":"Einstein, D. J. et al. National Cancer Institute\u2019s Working Group on biochemically recurrent prostate cancer: clinical trial design considerations. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO-25-01693.","DOI":"10.1200\/JCO-25-01693"},{"key":"1100_CR40","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.52971","volume":"8","author":"A Holzgreve","year":"2025","unstructured":"Holzgreve, A. et al. PSMA-PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with no metastatic disease by conventional imaging. JAMA Netw. Open. 8, e2452971 (2025).","journal-title":"JAMA Netw. Open."},{"key":"1100_CR41","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman, M. S. et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395, 1208\u20131216 (2020).","journal-title":"Lancet"},{"key":"1100_CR42","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737\u2013746 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR43","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James, N. D. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387, 1163\u20131177 (2016).","journal-title":"Lancet"},{"key":"1100_CR44","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith, M. R. et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N. Engl. J. Med. 386, 1132\u20131142 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR45","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi, K. et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet 399, 1695\u20131707 (2022).","journal-title":"Lancet"},{"key":"1100_CR46","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi, K. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377, 352\u2013360 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR47","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/ijc.34018","volume":"151","author":"ND James","year":"2022","unstructured":"James, N. D. et al. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int. J. Cancer 151, 422\u2013434 (2022).","journal-title":"Int. J. Cancer"},{"key":"1100_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi, K. N. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 381, 13\u201324 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR49","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis, I. D. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381, 121\u2013131 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR50","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","volume":"42","author":"F Saad","year":"2024","unstructured":"Saad, F. et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J. Clin. Oncol. 42, 4271\u20134281\u00a0(2024).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR51","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker, C. C. et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392, 2353\u20132366 (2018).","journal-title":"Lancet"},{"key":"1100_CR52","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos, C. E. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J. Clin. Oncol. 36, 1080\u20131087 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR53","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","volume":"30","author":"NW Clarke","year":"2019","unstructured":"Clarke, N. W. et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann. Oncol. 30, 1992\u20132003 (2019).","journal-title":"Ann. Oncol."},{"key":"1100_CR54","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","volume":"24","author":"CL Vale","year":"2023","unstructured":"Vale, C. L. et al. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. Lancet Oncol. 24, 783\u2013797 (2023).","journal-title":"Lancet Oncol."},{"key":"1100_CR55","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis, G. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 14, 149\u2013158 (2013).","journal-title":"Lancet Oncol."},{"key":"1100_CR56","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. 377, 338\u2013351 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR57","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/jcph.564","volume":"55","author":"KN Chi","year":"2015","unstructured":"Chi, K. N. et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. J. Clin. Pharmacol. 55, 1406\u20131414 (2015).","journal-title":"J. Clin. Pharmacol."},{"key":"1100_CR58","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","volume":"26","author":"G Attard","year":"2008","unstructured":"Attard, G. et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563\u20134571 (2008).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR59","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi, K. et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 20, 686\u2013700 (2019).","journal-title":"Lancet Oncol."},{"key":"1100_CR60","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/JCO.2025.43.5_suppl.20","volume":"43","author":"DJ Fisher","year":"2025","unstructured":"Fisher, D. J. et al. Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD). J. Clin. Oncol. 43, 20\u201320 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR61","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi, K. N. et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J. Clin. Oncol. 39, 2294\u20132303 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR62","doi-asserted-by":"publisher","first-page":"113290","DOI":"10.1016\/j.ejca.2023.113290","volume":"193","author":"AS Merseburger","year":"2023","unstructured":"Merseburger, A. S. et al. Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the randomised clinical TITAN study. Eur. J. Cancer 193, 113290 (2023).","journal-title":"Eur. J. Cancer"},{"key":"1100_CR63","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-24-0158","volume":"13","author":"K David","year":"2024","unstructured":"David, K. et al. Apalutamide-induced severe hypothyroidism: case series and practice recommendations for thyroid management. Eur. Thyroid J. 13, e240158 (2024).","journal-title":"Eur. Thyroid J."},{"key":"1100_CR64","doi-asserted-by":"publisher","first-page":"bvae105","DOI":"10.1210\/jendso\/bvae105","volume":"8","author":"C Moffatt","year":"2024","unstructured":"Moffatt, C. et al. The effect of apalutamide on thyroid function in prostate cancer patients. J. Endocr. Soc. 8, bvae105 (2024).","journal-title":"J. Endocr. Soc."},{"key":"1100_CR65","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","volume":"24","author":"CJ Sweeney","year":"2023","unstructured":"Sweeney, C. J. et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 24, 323\u2013334 (2023).","journal-title":"Lancet Oncol."},{"key":"1100_CR66","doi-asserted-by":"publisher","first-page":"5090","DOI":"10.1200\/JCO.2025.43.16_suppl.5090","volume":"43","author":"AY Zhang","year":"2025","unstructured":"Zhang, A. Y. et al. 8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304). J. Clin. Oncol. 43, 5090\u20135090 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR67","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1200\/JCO.21.00941","volume":"40","author":"MR Stockler","year":"2022","unstructured":"Stockler, M. R. et al. Health-related quality of life in metastatic, hormone-sensitive prostate cancer: ENZAMET (ANZUP 1304), an international, randomized phase III trial led by ANZUP. J. Clin. Oncol. 40, 837\u2013846 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR68","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/bcp.13425","volume":"84","author":"GE Benoist","year":"2018","unstructured":"Benoist, G. E. et al. Drug-drug interaction potential in men treated with enzalutamide: Mind the gap. Br. J. Clin. Pharmacol. 84, 122\u2013129 (2018).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1100_CR69","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong, A. J. et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 37, 2974\u20132986 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR70","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1200\/JCO.2025.43.16_suppl.5005","volume":"43","author":"AJ Armstrong","year":"2025","unstructured":"Armstrong, A. J. et al. ARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC). J. Clin. Oncol. 43, 5005\u20135005 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR71","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s13318-019-00577-5","volume":"44","author":"C Zurth","year":"2019","unstructured":"Zurth, C. et al. Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur. J. Drug. Metab. Pharmacokinet. 44, 747\u2013759 (2019).","journal-title":"Eur. J. Drug. Metab. Pharmacokinet."},{"key":"1100_CR72","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamaoncol.2020.7857","volume":"7","author":"A Ali","year":"2021","unstructured":"Ali, A. et al. Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 7, 555\u2013563 (2021).","journal-title":"JAMA Oncol."},{"key":"1100_CR73","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","volume":"76","author":"S Burdett","year":"2019","unstructured":"Burdett, S. et al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: A STOPCAP systematic review and meta-analysis. Eur. Urol. 76, 115\u2013124 (2019).","journal-title":"Eur. Urol."},{"key":"1100_CR74","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.euf.2024.06.009","volume":"11","author":"JE Bibault","year":"2025","unstructured":"Bibault, J. E., M\u00e9jean, A., Hyafil, F., Thibault, C. & Oudard, S. Radiation therapy for locally advanced prostate cancer: how do we treat patients with cN1 disease? Eur. Urol. Focus. 11, 76\u201378 (2025).","journal-title":"Eur. Urol. Focus."},{"key":"1100_CR75","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","volume":"404","author":"A Bossi","year":"2024","unstructured":"Bossi, A. et al. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2008\u00d7\u20082 factorial design. Lancet 404, 2065\u20132076 (2024).","journal-title":"Lancet"},{"key":"1100_CR76","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost, P. et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J. Clin. Oncol. 36, 446\u2013453 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR77","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips, R. et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 6, 650\u2013659 (2020).","journal-title":"JAMA Oncol."},{"key":"1100_CR78","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","volume":"40","author":"MP Deek","year":"2022","unstructured":"Deek, M. P. et al. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. J. Clin. Oncol. 40, 3377\u20133382 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR79","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","volume":"9","author":"C Tang","year":"2023","unstructured":"Tang, C. et al. Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the extend phase 2 randomized clinical trial. JAMA Oncol. 9, 825\u2013834 (2023).","journal-title":"JAMA Oncol."},{"key":"1100_CR80","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.euo.2024.03.010","volume":"7","author":"MP Deek","year":"2024","unstructured":"Deek, M. P. et al. Multi-institutional analysis of metastasis-directed therapy with or without androgen deprivation therapy in oligometastatic castration-sensitive prostate cancer. Eur. Urol. Oncol. 7, 1403\u20131410\u00a0(2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1100_CR81","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1200\/JCO.23.00041","volume":"41","author":"M Hussain","year":"2023","unstructured":"Hussain, M. et al. Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. J. Clin. Oncol. 41, 3595\u20133607 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR82","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1200\/JCO.2010.30.7025","volume":"28","author":"RM Franke","year":"2010","unstructured":"Franke, R. M., Carducci, M. A., Rudek, M. A., Baker, S. D. & Sparreboom, A. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J. Clin. Oncol. 28, 4562\u20134567 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR83","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","volume":"68","author":"G Gandaglia","year":"2015","unstructured":"Gandaglia, G. et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur. Urol. 68, 325\u2013334 (2015).","journal-title":"Eur. Urol."},{"key":"1100_CR84","doi-asserted-by":"publisher","first-page":"336.e1","DOI":"10.1016\/j.urolonc.2025.02.007","volume":"43","author":"F Urabe","year":"2025","unstructured":"Urabe, F. et al. Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: real-world data from a multicenter study. Urol. Oncol. 43, 336.e1\u2013336.e11 (2025).","journal-title":"Urol. Oncol."},{"key":"1100_CR85","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41391-020-0255-x","volume":"23","author":"R Iacovelli","year":"2020","unstructured":"Iacovelli, R. et al. The prognostic value of pain in castration-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 23, 654\u2013660 (2020).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1100_CR86","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.euo.2024.04.010","volume":"8","author":"D Sentana-Lledo","year":"2025","unstructured":"Sentana-Lledo, D. et al. Patient-reported quality of life and survival outcomes in prostate cancer: analysis of the ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED). Eur. Urol. Oncol. 8, 29\u201337 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"1100_CR87","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.clgc.2019.07.009","volume":"17","author":"K Mori","year":"2019","unstructured":"Mori, K. et al. Prognostic value of lactate dehydrogenase in metastatic prostate cancer: a systematic review and meta-analysis. Clin. Genitourin. Cancer 17, 409\u2013418 (2019).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1100_CR88","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1159\/000020289","volume":"38","author":"A Sella","year":"2000","unstructured":"Sella, A., Konichezky, M., Flex, D., Sulkes, A. & Baniel, J. Low PSA metastatic androgen- independent prostate cancer. Eur. Urol. 38, 250\u2013254 (2000).","journal-title":"Eur. Urol."},{"key":"1100_CR89","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00432-021-03642-2","volume":"148","author":"B Lim","year":"2022","unstructured":"Lim, B. et al. Biopsy-detected Gleason grade 5 tumor is an additional prognostic factor in metastatic hormone-sensitive prostate cancer. J. Cancer Res. Clin. Oncol. 148, 727\u2013734 (2022).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1100_CR90","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.eururo.2018.11.045","volume":"76","author":"AA Hamid","year":"2019","unstructured":"Hamid, A. A. et al. Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer. Eur. Urol. 76, 89\u201397 (2019).","journal-title":"Eur. Urol."},{"key":"1100_CR91","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41391-021-00430-4","volume":"25","author":"MG Velez","year":"2022","unstructured":"Velez, M. G. et al. Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 25, 479\u2013483 (2022).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1100_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-025-00936-1","author":"G Gebrael","year":"2025","unstructured":"Gebrael, G. et al. Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-025-00936-1 (2025).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1100_CR93","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.eururo.2021.09.030","volume":"81","author":"RP Graf","year":"2022","unstructured":"Graf, R. P. et al. Predictive genomic biomarkers of hormonal therapy versus chemotherapy benefit in metastatic castration-resistant prostate cancer. Eur. Urol. 81, 37\u201347 (2022).","journal-title":"Eur. Urol."},{"key":"1100_CR94","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.eururo.2024.12.015","volume":"87","author":"JS de Bono","year":"2025","unstructured":"de Bono, J. S. et al. Final overall survival and molecular data associated with clinical outcomes in patients receiving ipatasertib and abiraterone in the phase 3 IPATential150 trial. Eur. Urol. 87, 672\u2013682 (2025).","journal-title":"Eur. Urol."},{"key":"1100_CR95","doi-asserted-by":"publisher","first-page":"331.e13","DOI":"10.1016\/j.urolonc.2024.05.010","volume":"42","author":"S Custodio-Cabello","year":"2024","unstructured":"Custodio-Cabello, S. et al. Prognostic value of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC). Urol. Oncol. 42, 331.e13\u2013331.e24 (2024).","journal-title":"Urol. Oncol."},{"key":"1100_CR96","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","volume":"5","author":"W Abida","year":"2019","unstructured":"Abida, W. et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 5, 471\u2013478 (2019).","journal-title":"JAMA Oncol."},{"key":"1100_CR97","doi-asserted-by":"publisher","first-page":"TPS5129","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5129","volume":"43","author":"M Ong","year":"2025","unstructured":"Ong, M. et al. TRIPLE-SWITCH (SWOG\/CCTG-PR26): a randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924). J. Clin. Oncol. 43, TPS5129\u2013TPS5129 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR98","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","volume":"25","author":"AA Azad","year":"2024","unstructured":"Azad, A. A. et al. Sequential [(177)Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 25, 1267\u20131276 (2024).","journal-title":"Lancet Oncol."},{"key":"1100_CR99","doi-asserted-by":"crossref","unstructured":"Tagawa, S. T. et al. LBA6 \u2014 Phase III Trial of [177Lu]Lu-PSMA-617 Combined with ADT + ARPI in Patients with PSMA-positive Metastatic Hormone-Sensitive Prostate Cancer (PSMAddition) (ESMO Congress, 2025).","DOI":"10.1016\/j.annonc.2025.09.101"},{"key":"1100_CR100","doi-asserted-by":"publisher","first-page":"S999","DOI":"10.1016\/j.annonc.2024.08.1739","volume":"35","author":"M Padden-Modi","year":"2024","unstructured":"Padden-Modi, M. et al. 1658TiP The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: a phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT). Ann. Oncol. 35, S999\u2013S1000 (2024).","journal-title":"Ann. Oncol."},{"key":"1100_CR101","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2217\/fon-2023-0526","volume":"20","author":"N Agarwal","year":"2024","unstructured":"Agarwal, N. et al. TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. Future Oncol. 20, 493\u2013505 (2024).","journal-title":"Future Oncol."},{"key":"1100_CR102","doi-asserted-by":"publisher","first-page":"LBA5006","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5006","volume":"43","author":"G Attard","year":"2025","unstructured":"Attard, G. et al. Phase 3 AMPLITUDE trial: niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes. J. Clin. Oncol. 43, LBA5006\u2013LBA5006 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03961-8","author":"G Attard","year":"2025","unstructured":"Attard, G. et al. Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-025-03961-8 (2025).","journal-title":"Nat. Med."},{"key":"1100_CR104","doi-asserted-by":"publisher","first-page":"TPS5123","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5123","volume":"42","author":"KN Chi","year":"2024","unstructured":"Chi, K. N. et al. Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01). J. Clin. Oncol. 42, TPS5123\u2013TPS5123 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR105","doi-asserted-by":"publisher","first-page":"S998","DOI":"10.1016\/j.annonc.2024.08.1737","volume":"35","author":"S Howlett","year":"2024","unstructured":"Howlett, S. et al. 1656TiP The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: a phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT). Ann. Oncol. 35, S998\u2013S999 (2024).","journal-title":"Ann. Oncol."},{"key":"1100_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.004","author":"K Fizazi","year":"2025","unstructured":"Fizazi, K. et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.10.004 (2025).","journal-title":"Ann. Oncol."},{"key":"1100_CR107","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","volume":"398","author":"C Sweeney","year":"2021","unstructured":"Sweeney, C. et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet 398, 131\u2013142 (2021).","journal-title":"Lancet"},{"key":"1100_CR108","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","volume":"368","author":"M Hussain","year":"2013","unstructured":"Hussain, M. et al. Intermittent versus continuous androgen deprivation in prostate cancer. N. Engl. J. Med. 368, 1314\u20131325 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR109","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.2025.43.5_suppl.268","volume":"43","author":"A Sokolova","year":"2025","unstructured":"Sokolova, A. et al. Evaluating survival post-7 mo PSA response, stratified by response, disease extent, and intermittent vs. continuous ADT in mHSPC: The S9346 trial. J. Clin. Oncol. 43, 268\u2013268 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR110","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/ageing\/afp221","volume":"39","author":"PN Kannegaard","year":"2010","unstructured":"Kannegaard, P. N., van der Mark, S., Eiken, P. & Abrahamsen, B. Excess mortality in men compared with women following a hip fracture. national analysis of comedications, comorbidity and survival. Age Ageing 39, 203\u2013209 (2010).","journal-title":"Age Ageing"},{"key":"1100_CR111","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41584-024-01094-9","volume":"20","author":"NR Fuggle","year":"2024","unstructured":"Fuggle, N. R. et al. Evidence-based guideline for the management of osteoporosis in men. Nat. Rev. Rheumatol. 20, 241\u2013251 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1100_CR112","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-018-0510-0","volume":"13","author":"JA Kanis","year":"2018","unstructured":"Kanis, J. A., Johansson, H., Harvey, N. C. & McCloskey, E. V. A brief history of FRAX. Arch. Osteoporos. 13, 118 (2018).","journal-title":"Arch. Osteoporos."},{"key":"1100_CR113","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith, M. R. et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745\u2013755 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR114","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance, W. et al. Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J. Urol. 209, 1082\u20131090 (2023).","journal-title":"J. Urol."},{"key":"1100_CR115","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","volume":"32","author":"MR Smith","year":"2014","unstructured":"Smith, M. R. et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J. Clin. Oncol. 32, 1143\u20131150 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR116","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.2467","volume":"7","author":"W Fukuokaya","year":"2024","unstructured":"Fukuokaya, W. et al. Bone-modifying agents in patients with high-risk metastatic castration-sensitive prostate cancer treated with abiraterone acetate. JAMA Netw. Open. 7, e242467 (2024).","journal-title":"JAMA Netw. Open."},{"key":"1100_CR117","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","volume":"144","author":"RD Lopes","year":"2021","unstructured":"Lopes, R. D. et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation 144, 1295\u20131307 (2021).","journal-title":"Circulation"},{"key":"1100_CR118","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00345-020-03433-3","volume":"39","author":"P Davey","year":"2021","unstructured":"Davey, P. & Kirby, M. G. Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice. World J. Urol. 39, 307\u2013315 (2021).","journal-title":"World J. Urol."},{"key":"1100_CR119","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1200\/JCO.2013.49.5523","volume":"32","author":"JR Gardner","year":"2014","unstructured":"Gardner, J. R., Livingston, P. M. & Fraser, S. F. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J. Clin. Oncol. 32, 335\u2013346 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR120","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen, P. L. et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur. Urol. 67, 825\u2013836 (2015).","journal-title":"Eur. Urol."},{"key":"1100_CR121","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1470-2045(09)70338-9","volume":"11","author":"J Irani","year":"2010","unstructured":"Irani, J., Salomon, L., Oba, R., Bouchard, P. & Mottet, N. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol. 11, 147\u2013154 (2010).","journal-title":"Lancet Oncol."},{"key":"1100_CR122","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","volume":"401","author":"S Lederman","year":"2023","unstructured":"Lederman, S. et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet 401, 1091\u20131102 (2023).","journal-title":"Lancet"},{"key":"1100_CR123","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1056\/NEJMc2412361","volume":"392","author":"KL Lin","year":"2025","unstructured":"Lin, K. L., Shekar, S., Crumbaker, M. & Joshua, A. M. Neurokinin-3 receptor antagonism for refractory hot flashes in men. N. Engl. J. Med. 392, 202\u2013203 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1100_CR124","volume":"23","author":"D Sentana-Lledo","year":"2024","unstructured":"Sentana-Lledo, D., Saraf, A. & Morgans, A. K. Symptom burden and survivorship care for patients with prostate cancer on androgen deprivation therapy. J. Natl Compr. Canc. Netw. 23, e247047 (2024).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"1100_CR125","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41391-023-00785-w","volume":"27","author":"DE Hinojosa-Gonzalez","year":"2024","unstructured":"Hinojosa-Gonzalez, D. E. et al. Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 27, 507\u2013519 (2024).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1100_CR126","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/cncr.31153","volume":"124","author":"DJ McHugh","year":"2018","unstructured":"McHugh, D. J., Root, J. C., Nelson, C. J. & Morris, M. J. Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire? Cancer 124, 1326\u20131334 (2018).","journal-title":"Cancer"},{"key":"1100_CR127","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2019.04.031","volume":"116","author":"HJ Boyle","year":"2019","unstructured":"Boyle, H. J. et al. Updated recommendations of the international society of geriatric oncology on prostate cancer management in older patients. Eur. J. Cancer 116, 116\u2013136 (2019).","journal-title":"Eur. J. Cancer"},{"key":"1100_CR128","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41391-022-00541-6","volume":"26","author":"LG Briggs","year":"2023","unstructured":"Briggs, L. G. et al. Neurocognitive impairment associated with traditional and novel androgen receptor signaling inhibitors\u2009\u00b1\u2009androgen deprivation therapy: a pharmacovigilance study. Prostate Cancer Prostatic Dis. 26, 331\u2013337 (2023).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1100_CR129","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","volume":"87","author":"MR Smith","year":"2002","unstructured":"Smith, M. R. et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J. Clin. Endocrinol. Metab. 87, 599\u2013603 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1100_CR130","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.48707","volume":"7","author":"N Agarwal","year":"2024","unstructured":"Agarwal, N. et al. Physician reasons for or against treatment intensification in patients with metastatic prostate cancer. JAMA Netw. Open. 7, e2448707 (2024).","journal-title":"JAMA Netw. Open."},{"key":"1100_CR131","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","volume":"87","author":"S Gillessen","year":"2025","unstructured":"Gillessen, S. et al. Management of patients with advanced prostate cancer. report from the 2024 advanced prostate cancer consensus conference (APCCC). Eur. Urol. 87, 157\u2013216 (2025).","journal-title":"Eur. Urol."},{"key":"1100_CR132","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong, A. J. et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 40, 1616\u20131622 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR133","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.euros.2024.06.006","volume":"66","author":"ME Ahmed","year":"2024","unstructured":"Ahmed, M. E. et al. Survival patterns based on first-site-specific visceral metastatic prostate cancer: are outcomes of visceral metastases the same? Eur. Urol. Open. Sci. 66, 38\u201345 (2024).","journal-title":"Eur. Urol. Open. Sci."},{"key":"1100_CR134","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/cncr.22971","volume":"110","author":"PE Spiess","year":"2007","unstructured":"Spiess, P. E. et al. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer 110, 1729\u20131737 (2007).","journal-title":"Cancer"},{"key":"1100_CR135","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.37871","volume":"7","author":"A Goldkorn","year":"2024","unstructured":"Goldkorn, A. et al. Circulating tumor cell count and overall survival in patients with metastatic hormone-sensitive prostate cancer. JAMA Netw. Open. 7, e2437871 (2024).","journal-title":"JAMA Netw. Open."},{"key":"1100_CR136","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/pros.24787","volume":"84","author":"F Matrone","year":"2024","unstructured":"Matrone, F. et al. Prognostic value of circulating tumor cells in oligorecurrent hormone-sensitive prostate cancer patients undergoing stereotactic body radiation therapy. Prostate 84, 1468\u20131478 (2024).","journal-title":"Prostate"},{"key":"1100_CR137","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.clgc.2022.06.016","volume":"20","author":"AM Lee","year":"2022","unstructured":"Lee, A. M. et al. The prognostic significance of homologous recombination repair pathway alterations in metastatic hormone sensitive prostate cancer. Clin. Genitourin. Cancer 20, 515\u2013523 (2022).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1100_CR138","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1200\/JCO.23.02182","volume":"42","author":"BL Heiss","year":"2024","unstructured":"Heiss, B. L. et al. US food and drug administration approval summary: talazoparib in combination with enzalutamide for treatment of patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. J. Clin. Oncol. 42, 1851\u20131860 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1100_CR139","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1158\/1078-0432.CCR-20-0168","volume":"26","author":"KH Stopsack","year":"2020","unstructured":"Stopsack, K. H. et al. Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer. Clin. Cancer Res. 26, 3230\u20133238 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1100_CR140","doi-asserted-by":"publisher","first-page":"S961","DOI":"10.1016\/j.annonc.2024.08.1677","volume":"35","author":"E Grist","year":"2024","unstructured":"Grist, E. et al. 1596O decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): An ancillary study of the STAMPEDE docetaxel trials. Ann. Oncol. 35, S961\u2013S962 (2024).","journal-title":"Ann. Oncol."},{"key":"1100_CR141","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","volume":"25","author":"MJ Karpinski","year":"2024","unstructured":"Karpinski, M. J. et al. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. Lancet Oncol. 25, 1188\u20131201 (2024).","journal-title":"Lancet Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01100-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01100-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01100-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T13:01:58Z","timestamp":1769518918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01100-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":141,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1100"],"URL":"https:\/\/doi.org\/10.1038\/s41571-025-01100-3","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"29 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.M.B. is a member of the ANZUP Scientific Advisory Committee (unpaid). L.E. reports research grant support (to institution) from Clarity Pharma and Novartis and consulting fees for lectures or advisory boards from Advancell, Astellas, AstraZeneca, Clarity Pharma, Janssen, Novartis and Telix in the past 5\u2009years. C.J.S. declares roles as principal investigator of the CHAARTED trial, study co-chair of the ENZAMET trial and is a member of the ANZUP Scientific Advisory Committee (unpaid); research funding (to institution) from Astellas, Bayer, Janssen, Pfizer and Sanofi; compensated advisory roles for Astellas, Bayer, Genentech\/Roche, Hengrui, Janssen, Lilly, Novartis, Pfizer, PointBiopharma and Sanofi; and stock ownership in Leuchemix. C.J.S also holds patents for parthenolide as an anticancer agent, co-authored with H. Nakshatri (WO0145699A1, owned by Indiana University); for use of the drug combination of abiraterone and cabozantinib to treat prostate cancer, co-authors with P. Kantoff (WO 2014\/165770 A1 owned by Exelixis); for compositions and methods for screening and diagnosis of prostate cancer with KDM5D biomarker, co-authored with P. Kantoff, G.-S. Mary Lee and K. Komura (WO2017\/117486 A1, owned by Dana-Farber Cancer Institute); for compositions and methods for screening and identifying clinically aggressive prostate cancer with SNPs and ZFP36, co-authored with C. Huttenhower, T. Gerke, L. Mucci, G.-S. Mary Lee and D. Bornigen (WO2017127696A, owned by Harvard University and Dana-Farber Cancer Institute). M.A.C. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}